Sentences with phrase «with abiraterone»

Patients treated with abiraterone had hypertension, hypokalemia, and elevated liver enzymes.

Patients with metastatic castration - resistant prostate cancer (CRPC) had higher prostate - specific antigen (PSA) response when treated with enzalutamide compared with abiraterone / prednisone, but had no difference in time to progression or time to PSA progression, according to the results of a study (abstract 5002) presented by Kim N. Chi, MD, of the British Columbia Cancer Agency in Vancouver, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2 — 6.

Among the group of men who had non-metastatic and metastatic disease who had not received prior treatment with abiraterone and enzalutamide, data for 60 were available for analysis.

Several clinical centres in the USA and Canada recruited four groups of men with CRPC to a phase II study to receive 2550 mg of galeterone orally once a day: 22 men had CRPC that had not metastasised (spread) and had received no previous treatment; 39 men had metastatic CRPC and no previous treatment with abiraterone or enzalutamide; 37 and nine men had metastatic CRPC and had failed treatment with abiraterone and enzalutamide respectively.

Not exact matches

«Recent data have shown that a variant of the androgen receptor called AR - V7, found in tumour cells circulating in the blood of patients with metastatic CRPC, predicted resistance to treatment with enzalutamide and abiraterone,» she will say.

The results from the Cancer Research UK - funded STAMPEDE trial could change the standard of care for men with prostate cancer, making abiraterone a first - line treatment alongside hormone therapy.

Associate professor Mary - Ellen Taplin, of the Dana - Farber Cancer Institute, Boston, USA, will tell the 26th EORTC - NCI - AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, that galeterone was well tolerated by patients in the ARMOR2 trial, and also lowered PSA levels in a subset of men with CRPC that was resistant to other drugs that target the cancer, such as enzalutamide and abiraterone.

Abiraterone, taken with prednisone to prevent side effects, «represents a new standard of care for metastatic disease,» according to a recent review article in the New England Journal of Medicine.

Abiraterone's ability to lower levels of prostate - specific antigen, a surrogate marker for prostate cancer, was slightly greater for patients in the low - dose with food group when measured at 12 weeks.

The amount of abiraterone that gets absorbed and enters the blood stream can be multiplied four or five times if the drug is swallowed with a low - fat meal (7 percent fat, about 300 calories).

While the outlook of patients with this gene variant is poor, these studies offer hope for a new treatment strategy for these men, and more studies are needed using next - generation androgen inhibitors, such as abiraterone and enzalutamide.

Furthermore, they found that D4A is more effective than abiraterone at killing aggressive prostate cancer cells, suggesting that some patients may benefit from direct treatment with D4A.

Cleveland Clinic researcher Nima Sharifi, M.D., found that abiraterone, a steroid inhibitor, is converted into the more physiologically active D4A (Δ4 - abiraterone) in both patients and animal models with prostate cancer who take the drug.

«More studies are needed to uncover the exact mechanisms involved, but we predict that direct treatment with D4A could prolong survival in some patients with metastatic prostate cancer,» said Dr. Sharifi, «Further studies will also help us develop a potential biomarker profile to predict which patients will respond to D4 — abiraterone.»

A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza) versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration - Resistant Prostate Cancer who have Failed Prior Treatment with a New Hormonal Agent and have Homologous Recombination Repair Gene Mutations.

Similarly, the time to unconfirmed PSA progression was 8.0 months for enzalutamide compared with 7.4 months for abiraterone (HR, 0.83; 95 % CI, 0.59 — 1.17; P =.283).

In addition, 20 % of patients assigned abiraterone had a rising PSA as best response compared with 10 % of patients assigned enzalutamide (P =.0501).

A new study found that patients with mCRPC had higher PSA response with enzalutamide vs abiraterone, but no difference in time to progression, and reported worse outcomes in those with quantifiable ctDNA.

We carried out a multicentre single - arm phase II trial in women with AR - positive, estrogen, progesterone receptor and HER2 - negative (triple - negative) metastatic or inoperable locally advanced BC to assess the efficacy and safety of abiraterone acetate (AA) plus prednisone.

Patient 2 was diagnosed with widespread metastatic prostate cancer in 2013 and progressed on numerous systemic therapies, including leuprolide, bicalutamide, enzalutamide, abiraterone, and eventually docetaxel.

Investigators said they found that taking Zytiga (abiraterone acetate) with a low - fat breakfast boosts its efficiency.